MTIF 2018 Speaker Bios
Darryl Barnes, MD, CEO, Sonex Health
Dr. Barnes is the CEO and co-founder of Sonex Health and a co-inventor of the SX-One MicroKnife ® . Dr. Barnes was recently awarded the Medical Devices CEO of the Year 2018 - Upper Midwest USA and the Most Outstanding Health Tech Innovator - Upper Midwest USA by CEO Monthly. He as a long and fruitful history of innovation in the medical device industry, having been awarded numerous patents for technology currently being used all over the country. Some of those include inventions licensed to Tenex Health, another company dedicated to providing minimally invasive treatment options.
Jim Boylan, President & Head of Investment Banking, Leerink Capital
James (Jim) Boylan is the President of Leerink Partners and the Head of Investment Banking, having joined the firm in 2009. Mr. Boylan has 20+ years of experience in healthcare investment banking. Prior to joining Leerink Partners, Mr. Boylan was at Merrill Lynch & Co. for 12 years where he was a Managing Director in the healthcare group from 2005-2009 and a Managing Director in the Mergers & Acquisitions department from 1997-2004. Mr. Boylan’s deal experience includes more than 100 transactions where he has helped his clients complete the full cadre of M&A and financing transactions across the pharma / biotech, medical devices, healthcare services and diagnostics & life science tools sectors. Mr. Boylan earned his MBA from Columbia University and a B.S. from Lehigh University.
Taylor Carol, Chief Evangelist, ZOTT, Co-Founder, Game Changer Charity
During his five-year battle with a then-terminal cancer diagnosis, Taylor Carol witnessed the immense impact that video games and entertainment technology had on patients’ lives. Inspired, he resolved to build a nonprofit committed to leveraging gaming, technology, and innovation to empower patients to play, learn, and socialize. Despite missing nearly five years of school, Mr. Carol, now a 23-year old Harvard Graduate, has taken GameChanger Charity from a garage hobby to an international endeavor. It now partners with the largest tech companies on earth, like Amazon, to support over 20,000 children in 100 hospitals around the world. Witnessing the desperate need for these services, Mr. Carol and the GameChanger team created “businesses around the charity,” to both promote the GameChanger vision into the for-profit space and to ensure that GameChanger Charity always had the means to support its patient populations. In recent years, the GameChanger team has created ZOTT: A for-profit subsidiary owned in majority by GameChanger Charity. ZOTT is a cloud-based content distribution platform designed to revolutionize hospitals’ patient engagement systems. Both the ZOTT and GameChanger Charity teams are thrilled to reimagine the ways in which the for-profit and nonprofit sectors can harness technology to change patients’ lives forever.
Bill Carpou, CEO, OCTANe
Bill Carpou is the chief executive officer of OCTANe. Prior to joining OCTANe as CEO, Mr. Carpou served as an operating partner at the private equity firm, Blackstone including leading a key portfolio company. Mr. Carpou was recruited to this position by Blackstone and responsible for all aspects of revenue including sales, marketing, channel expansion, strategic alliances, acquisitions and customer service.
Anthony Chang, Chief Intelligence Officer, CHOC
Dr. Chang attended Johns Hopkins University for his B.A. in molecular biology prior to entering Georgetown University School of Medicine for his M.D. He then completed his pediatric residency at Children’s Hospital National Medical Center and his pediatric cardiology fellowship at Children’s Hospital of Philadelphia. He accepted a position as attending cardiologist in the cardiovascular intensive care unit of Boston Children’s Hospital and as assistant professor at Harvard Medical School. He has been the medical director of several pediatric cardiac intensive care programs (including Children’s Hospital of Los Angeles, Miami Children’s Hospital, and Texas Children’s Hospital). He is currently the Chief Intelligence and Innovation Officer and Medical Director of the Heart Failure Program at Children’s Hospital of Orange County. He has also been named a Physician of Excellence by the Orange County Medical Association multiple years. He has completed a Masters in Business Administration (MBA) in Health Care Administration at the University of Miami School of Business and graduated with the McCaw Award of Academic Excellence.
Dominique Chapman, Director of Business Development & Integration, Chair of Medtronic’s Women’s Network, Irvine, Medtronic
Dominique Worthington is the Director of Integration and Strategy Deployment for Medtronic’s RTG - Brain Therapies group. Ms. Worthington has over 25 years of industry experience in both large companies and start-ups. Ms. Worthington is the chair of the Medtronic Woman’s Network for Irvine an employee resources group dedicated to reaching the goal of 40% women in leadership by year 2020. During her tenure at Medtronic, she has led integration activities for Medtronic’s acquisition of the Covidien Neurovascular group and several strategic acquisitions for the Neurovascular business. Prior to Medtronic, Ms. Worthington was with Edwards Lifescience where she held key leadership positions in Strategy, Operations, Planning and Information Technology. In addition, Ms. Worthington has held executive leadership positions in several successful technology start-up companies. Ms. Worthington holds a bachelor’s degree in decision science from Georgia State University and a Master of Business Administration from Chapman University.
Michael Cloutier, Founding Partner & CEO, Accelera Canada
Mike Cloutier is an accomplished business leader and consultant with over 38 years in the Life Sciences sector. Over the past 20 years, Mike was General Manager, President and CEO of Five major pharmaceutical firms and Canadian Diabetes Association (now Diabetes Canada). Most recently, Mike founded a Canadian based global consulting practice, Accelera Canada Ltd. Accelera Canada provides unique and unparalleled “one top support” to US and European based biotech/pharmaceutical companies exploring commercial entry to Canada.www.acceleracanada.com
Nick Desai, CEO, Heal
Nick Desai is an accomplished entrepreneur who has started and led four successful start-ups over the last 18 years. Currently, Nick is the CEO of Heal – a company he founded to re-boot the US healthcare system leveraging the transformative power of technology enabled doctor house calls. In just over 3 years, Heal has raised over $65 million in investment capital, delivered over 60,000 house calls an driven over $41 million in healthcare cost savings. Nick’s previous start-ups have been award-winning and innovative leaders in technology-enabled fitness and weight loss, social media and mobile applications, and the web’s first self-updating address book.
Linda DiMario, Executive Vice President, Greater Irvine Chamber
Linda DiMario helps lead the most influential Chamber in Orange County and the economic development and tourism initiatives designed to help businesses grow and enhance the economic vitality of Irvine. Before joining the Chamber, DiMario was the owner and principal of DiMario & Associates, an economic development, community branding and tourism consulting practice, working with over 100 cities, counties and organizations in the U.S. to help communities compete better in a global economy, leverage their strengths and transform or re-invent their economies. Prior to her consulting practice, DiMario was president and CEO of the Arlington (Texas) destination marketing organization for six and half years where she led a 30% increase in tourism business, worked with MLB’s Texas Rangers and was part of the leadership team to campaign for, build and secure the new Dallas Cowboys Stadium. Before moving to Texas, DiMario helmed the Long Beach Area destination marketing organization for over seven years as president & CEO. DiMario also served as Vice President, Greater Tucson destination marketing organization. DiMario is on the Board of Directors and a mission specialist for the International Economic Development Council (IEDC) and a former Board member of Destination Marketing Association International (DMAI). She is the recipient of many awards including Belle Lowe Woman of the Year, Soroptomists Woman of the Year for Economic Development, California State Legislative District Woman of the Year, ACOM Executive Excellence Award and other community recognitions. DiMario holds a bachelor’s degree in political science from Central Washington State University and is a Vietnam War-era Air Force veteran.
Harrison Fox, Product Manager, SAP
Harrison currently serves as Director of Product Management for SAP’s Health Application Innovation Team and as a fellow at the SAP Innovation Center in Southern California. The SAP Health Application Innovation group develops and delivers innovative applications that help clinicians and health systems improve their operational effectiveness while ensuring patients have the best possible outcomes. Harrison previously served as Executive Director of a startup that developed and deployed clinical applications to reduce medical errors and improve patient care by fostering cross organizational sharing of clinical data and integrated clinical decision support. In addition, he also worked with a team at Columbia University Medical School to successfully improve vaccination rates for children in New York City by over 20% through mobile phone based interventions. Harrison received his Masters of Public Health from Columbia University in the City of New York with a focus in Health Policy and Management and BA degrees in Biochemistry and Molecular, Cellular and Developmental Biology from the University of Colorado.
Michael Hedge, Managing Partner, K&L Gates
Michael Hedge is a partner in the firm's Orange County office. His practice focuses on securities, mergers and acquisitions, corporate finance, venture capital, corporate governance and commercial transactions. Mr. Hedge has extensive experience in representing public companies in securities offerings, mergers and acquisitions and stock exchange compliance matters. Mr. Hedge also regularly works with private equity funds in acquisition transactions and fund formation. Mr. Hedge has substantial experience in the medical device, pharmaceutical and technology industries.
Julie Hill, Board of Directors, Anthem; Chair, UC Irvine Board of Trustees
Julie Hill is a member of the board of directors of Anthem (a Fortune 50 company and the largest U.S. health insurance company by member), the Lord Abbett Family of Funds, (a $160 billion New York-based mutual fund management firm), and was previously on the board of Lend Lease, and other public company boards, based in Sydney, Australia, (a $7 billion international construction, development, investment and management firm, publicly traded on the Australian exchange.) Ms. Hill founded Hillsdale Development, a home building and land development company based in Newport Beach, California, in 1998, and The Hill Company, which has a portfolio of interests. From 1991-1998, Ms. Hill was president and Chief Executive Officer in the US of Costain Homes, a division of the Costain Group based in London, England. She was previously a senior executive with Mobil Land Development Corporation in Atlanta, Georgia, a division of Mobil Oil.
Justin Klien, Partner, New Enterprise Associates, MD, JD
Justin joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments.He serves as a director of Advanced Cardiac Therapeutics, Cartiva, ChromaCode, FIRE1, Intact Vascular, Personal Genome Diagnostics, PhaseBio Pharmaceuticals, Relievant Medsystems, Senseonics (NYSE: SENS), VertiFlex, Vesper Medical, and VytronUS. Justin’s past board memberships and investments include CV Ingenuity (acquired by Covidien), Nevro (NYSE: NVRO), Topera (acquired by Abbott), TriVascular (NASDAQ: TRIV), and Ulthera (acquired by Merz). He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed's Business Development Committee.
Christy Lea, Partner, Knobbe Martens
Christy is a partner in the Orange County office of Knobbe Martens specializing in intellectual property (IP) law where she co-manages the medical device litigation group. She has represented clients in the medical device and pharmaceutical industries for nearly two decades, including Smith & Nephew and Edwards Lifesciences. Notably, Christy co-led the trial team that won $112M for client CardiAQ Valve Technologies (acquired by Edwards Lifesciences for $400M) in a trade secret dispute with a vendor. Christy has been named a “Life Science Star” by Legal Media Group (LMG) Life Sciences, a “Woman to Watch” by the American Intellectual Property Law Association (AIPLA), a “Top 10 Life Sciences Litigator” by Managing IP magazine, and a Southern California “Rising Star” in intellectual property law by Super Lawyers magazine.
Sabing Lee, Partner, Knobbe Martens
Sabing H. Lee is a partner in the Orange County office of Knobbe, Martens, Olson & Bear, LLP. Mr. Lee received his bachelor’s degree in Materials Engineering, Phi Beta Kappa and summa cum laude, from UCLA, and also received his master’s degree in Materials Science and Engineering from UCLA. He received his J.D. from the University of California, Berkeley School of Law (Boalt Hall), where he was an Articles Editor and Executive Editor for the Berkeley Technology Law Journal. Mr. Lee’s practice includes strategic patent procurement, patent portfolio management, intellectual property due diligence and general counseling on infringement, licensing, interferences and post-grant proceedings. Mr. Lee currently represents clients in a wide range of technologies, with an emphasis on medical devices and procedures and materials science.
Raj Makkar, MD, Cardiologist, Cedars Sinai
Dr. Raj Makkar received his Bachelor of Science from Gujarat University, in India and his MD from the KM School of P.G. Medicine. He currently holds the position as the Director of Interventional Cardiology and Cardiac, as well as the Professor of Medicine, at the University of California. He is Chair in Interventional Cardiology and Associate Director, Heart Institute for Interventional Technologies at Cedars-Sinai hospital.
Jim Mazzo, Global President of Ophthalmic Devices, Zeiss
James V. Mazzo is Global President for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and Refractive Lasers. He also heads the company’s U.S. Sales and Service Center. Mazzo is one of the ophthalmic industry’s most respected leaders with over 36 years of experience, including 22 years leading Allergan’s North American and European eye care organizations; 7 years as Chairman, President and CEO of Advanced Medical Optics (AMO); 4 years as EVP of Abbott’s global ophthalmology business; 3 years as Executive Chair and CEO of AcuFocus; has served as Board Chairman, AdvaMed. Additionally, Mazzo is Chairman of Neurotech; on the board of OCTANe, RPS, Iantech; on the University of California at Irvine foundation; Executive Committee Board Member with MDMA.
Rob Michiels, Former CEO, CardiAQ Valve Technologies
Rob Michiels is a global, multilingual executive with an extensive track record in the management of medical device companies, both within large corporate and start-up environments. Skilled at spearheading the global development and commercialization of emerging technologies, he combines operations management, sales, marketing and business development expertise with technology skills and regulatory/environmental knowledge. He most recently served as CEO of CardiAQ Valve Technologies, a venture funded start-up developing Transcatheter Mitral Valve Implantation, which was acquired by Edwards Lifesciences during the second half of 2015. He previously served as President and COO of CoreValve, a venture funded start-up that developed one of the two leading Transcatheter Aortic Valve Implantation technologies (acquired by Medtronic in 2009) and as President and COO of InterVentional Technologies, a venture funded start-up that developed several key interventional cardiology devices (acquired by Boston Scientific). He is also a founding partner of CONSILIUM, a medical device market research company active in identifying, funding and greenhousing start-up technologies. He is currently a director of EDAP TMS, Aegis Surgical Ltd, Atrius Ltd, and FEops NV, all companies developing cutting edge less invasive technologies. Fluent in English, French and Dutch, he holds a bachelor's degree in economics from Antwerp University in Belgium and an MBA from Indiana University.
David Mildrew, Managing Director, BioQuest
Since joining BioQuest in 2001, which was acquired by Diversified Search in 2016, Dave Mildrew has teamed with CEOs, senior executives, and board members to find the right leaders for fast-growing healthcare organizations. His specialty is building leadership teams for emerging companies, with a mandate for fast growth. Before entering the field of executive search, Mildrew spent more than 30 years working in the healthcare industry, including in senior-level roles and as a human resources executive for global corporations including Pfizer, Medtronic, CareMark, and Tokos Medical. As Vice President, Human Resources at CareMark and Tokos, Mildrew played a key role in growing the organizations from emerging startups into large public companies. He was also instrumental in hiring the senior leaders who led IPOs and subsequent strategic acquisitions.
Jonathan Norris, Managing Director, Silicon Valley Bank – Life Science & Healthcare Practice
Jonathan Norris is a managing director of sales origination for Silicon Valley Bank. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many life science and healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on limited partnership allocations. In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than sixteen years of banking experience working with healthcare companies and venture capital firms. Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.
Stacey Pugh, VP & General Manager, Neurovascular, Medtronic
Stacey Pugh is Vice President and General Manager of Medtronic’s Neurovascular business where she provides overall global strategic leadership, guides marketing and business development and is responsible for revenue growth. Prior to this role, Stacey was Vice President of Medtronic’s Neurovascular international business unit and was responsible for leading the company’s European, Middle Eastern and African (EMEA) business programs and developing trade strategies to support the global revenue and market share growth of Medtronic Neurovascular products. She has more than 15 years of experience in medical device research, development and commercialization. Prior to this position, Stacey held various leadership roles in Covidien’s Neurovascular division for almost three years as Vice President of Global Medical Affairs, Vice President of Clinical Affairs and Senior Director of Clinical Affairs, where she provided strategic direction for all medical affairs activities and executed strategic market access plans.
Dr. Arshad Quadri, Founder, CardiAQ Valve Technologies
Dr. Arshad Quadri, MD., founded CardiAQ Valve Technologies, Inc. in 2007 and serves as its Chairman and Chief Marketing Officer. Dr. Quadri serves as an Attending Cardiac Surgeon at St. Francis Hospital, Hartford, CT. Dr. Quadri serves as a Director of CardiAQ Valve Technologies, Inc.
Mahmood Razavi, MD, Interventional Radiologist, St. Joseph Health
Dr. Razavi is the founder or co-founder of 4 medical device companies with an exit value of over $650,000,000 and has served on the Board of Directors and/or the Scientific and strategic Advisory Boards of many device and biotechnology companies. He is currently the Director of the Center for Clinical Trials and Research at St Joseph Heart and Vascular Center in Orange, California. Prior to this, he was an Associate Professor at the Stanford University Medical Center and the Director of the fellowship program at the Vascular & Interventional Section. He had also served as the Acting Chief of Interventiojnal Radiology at the Stanford University Hospital. To date, he has authored or co-authored over 280 scientific publications, abstracts, and book chapters and has been the recipient of many honors and awards from various professional medical societies. He has been the recipient of several industry, institutional and federal grants and has given over 600 invited lectures at National & International meetings.
JC Ruffalo, Director of LaunchPad SBDC and Investor Relations, OCTANe
JC Ruffalo joined the OCTANe team in June 2014 and is the Director of LaunchPad SBDC and Investor Relations. JC graduated from Chapman University Argyros School of Business in 2011 with a business administration degree with an emphasis in Entrepreneurship and Economics. Since his graduation he co-founded a small startup (Double Splash Media), which was involved with email marketing. After Double Splash Media, JC worked for LKQ, a large corporation that is the world’s largest supplier of automotive replacement parts, as a buyer and general manager.
Renee Compton Ryan, Vice President of Venture Investments, Johnson & Johnson Innovation
Renee is Vice President of Investments at the Johnson & Johnson Development Corporation, and is based at the Johnson & Johnson Innovation Center in California. Renee supports the investments for our Medical Devices and Diagnostics businesses and is a passionate supporter of medical innovation.Formerly, Renee was a Managing Director at Baird in Palo Alto, CA overseeing the medical device investment banking practice. Prior to Baird, Renee oversaw the build out of the West Coast healthcare investment banking practice at Jefferies & Co. In total, Renee has approximately 20 years of healthcare investment banking experience at firms such as Goldman Sachs and Credit Suisse. She has structured over $15 Billion of transactions during this time including M&A, venture financing and public offerings of debt and equity. Renee earned her B.A. in economics at Georgetown University in Washington, D.C., and an MBA from Columbia University
Henry Samueli, Co-Founder, CTO & Chairman, Broadcom
Henry Samueli is the Chief Technical Officer and a board member at Broadcom. He is responsible for driving the company vision for engineering research and development activities. Prior to his current role, Dr. Samueli was Co-Founder, Chairman of the Board and Chief Technical Officer for Broadcom Corporation. Dr. Samueli serves as a professor in the Electrical Engineering Department at the University of California, Los Angeles (UCLA) and as a Distinguished Adjunct Professor in the Electrical Engineering and Computer Science Department at the University of California, Irvine (UCI). Previously, Dr. Samueli held a variety of engineering management positions at TRW.
Steven L. Small, MD, PhD, Professor of Neurology & Director & Chief Scientific Officer, Medical Innovation Institute, UC Irvine Health School of Medicine
Steven L. Small, Ph.D., M.D., is Professor of Neurology, as well as Director and Chief Scientific Officer of the Medical Innovation Institute at the University of California, Irvine. He is also Professor Emeritus at The University of Chicago. He was the Chair of the Neurology from 2010-2017. As a scientist, Dr. Small has been a pioneer in understanding the anatomy and physiology of the human brain and its relation to function by direct investigation of human subjects though the use of advanced techniques in brain imaging. This work has encompassed the study of normal adults, typically developing children, and both adults and children with stroke. In earlier research, Dr. Small focused on artificial intelligence algorithms for processing natural language. As neurology departmental chair, Dr. Small doubled department size and expanded significantly the volume and quality of neurological services for the only academic medical center in Orange County, California, the sixth largest county in the United States.
Ali J. Satvat, Director of Healthcare Private Equity, KKR
Ali J. Satvat (Menlo Park) joined KKR in 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. He leads KKR’s Health Care Strategic Growth investing efforts and sits on the Health Care Strategic Growth Investment Committee and the Health Care Strategic Growth Portfolio Management Committee. He currently serves on the boards of directors of AcuFocus, Arbor Pharmaceuticals, Blue Sprig Pediatrics, BridgeBio Pharma, Cohera Medical, Coherus BioSciences, PRA Health Sciences, Slayback Pharma and Trilogy MedWaste and is also involved in KKR’s investments in Ajax Health and Spirox. Prior to joining KKR, Mr. Satvat was a principal with Apax Partners, where he invested in health care and was actively involved with many of the firm’s successful private equity and growth equity investments. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group. Mr. Satvat holds an A.B., magna cum laude, in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat is a member of the board of directors of the Healthcare Private Equity Association.
Michael Seres, Founder & CEO, 11 Health
Michael is the founder of 11Health, the world’s first sensor network company focused on helping patients with long term chronic conditions who are connected to medical bags. He was diagnosed aged 12 with the incurable bowel condition Crohn's Disease. In late 2011 he became the 11th person to undergo a small bowel transplant in the UK at The Churchill Hospital in Oxford. More recently he is a two time cancer survivor. Michael started blogging about his journey and is a published author and patient mentor. He was the co-Chair of NHS Digital Services User Council & helped implement the first skype clinics in UK. In 2015 he was announced as Stanford Medicine X first Patient-in-Residence and is an Executive Board member.
Carrie Strom, Vice President of Aesthetic and Regenerative Medicine, Allergan
Carrie Strom is the Vice President of Marketing for Allergan’s US Plastic and Regenerative Medicine business, which includes Alloderm, Artia, Strattice, Revolve, Natrelle implants and tissue expanders, and the Keller Funnel. Carrie was the commercial lead for Allergan’s acquisition and integration of LifeCell in 2017. Her current responsibilities include overseeing the downstream marketing teams, as well as contracting, reimbursement and medical education. Carrie leads the strategic direction for the portfolio in both the reconstructive and cash-pay settings, for both plastic and general surgery specialties. Carrie joined Allergan in 2011 as a Product Director on the US Urology Marketing Team to launch BOTOX Therapeutic for its first indication in Urology, and was then promoted to Senior Director of Marketing on the US Neuro-Rehab Marketing Team where she lead BOTOX Therapeutic marketing efforts and new indication planning for Spasticity and Movement Disorders. In 2014 she was promoted to VP of sales and marketing for the US Plastic Surgery business, and also assumed responsibility of marketing for SkinMedica, Allergan’s physician dispensed skincare line. Prior to joining Allergan, Carrie spent 11 years at Pfizer in roles of increasing responsibility, starting as a sales rep and moving to NYC as the Marketing Director for LIPITOR. Carrie is a member of the Board of Directors for the OC Affiliate of Susan G Komen. She lives in Corona del Mar, CA with her husband, 8 year old daughter, and 5 year old son.
Keith Studdard, Vice President, Government Affairs & Political Strategy, Jeffrey J. Kimbell & Associates
Mr. Studdard spent two and a half years in the House of Representatives serving as Legislative Director to U.S. Representative Marsha Blackburn (R-TN). Blackburn currently serves as Vice Chair of the House Energy and Commerce Committee where she sits on four critical subcommittees including the Subcommittee on Health and Subcommittee on Oversight and Investigations. She also serves on the House Budget Committee and is a founding member of the Republican Women’s Policy Committee. Finally, Rep. Blackburn is a House Deputy Whip and serves as a Vice-Chairman of the National Republican Congressional Committee.During his time with Rep. Blackburn, Keith was involved in debate and negotiations over numerous pieces of health care related legislation including the Affordable Care Act, the Food and Drug Administration Safety and Innovation Act, and the Drug Quality and Safety Act.
Katie Szyman, Corporate Vice President & General Manager, Edwards Lifesciences
Katie Szyman was named Corporate Vice President of the Critical Care and Vascular business at Edwards Lifesciences in 2014 and is a member of the company’s Executive Leadership Team. Szyman has more than 20 years of experience in the medical device industry including senior management positions and international assignments with Medtronic, where she most recently served as Senior Vice President of Channel Management. Prior to that, she was President of its global diabetes business, overseeing research, development, operations, sales and marketing for the company’s insulin infusion pumps and continuous glucose monitoring systems. Additionally, she held a variety of leadership roles at the company, including Senior Vice President of Corporate Strategy and Innovation, Vice President and General Manager of Endovascular Innovations, and Vice President of Finance for the vascular business. Szyman previously served on the boards of Tornier, Inspire Medical Systems, and the California Healthcare Institute (CHI). She graduated from the University of St. Thomas and earned her master’s degree in business administration from Harvard Business School.
Troy Varenchik, Partner, Deloitte
Troy Varenchik has over 20 years of tax experience and serves his clients as the Lead Tax Partner responsible for implementing the tax compliance and consulting work plan and day-to-day management of the engagement, our people, and the overall quality delivered by Deloitte. Troy has extensive experience serving acquisitive companies in the life sciences, technology, and manufacturing industries, working with the executives at the operating company level as well as directly with the investors. Troy actively consults his clients regarding the implications and planning opportunities related to new tax legislation. He has extensive experience working with technology companies and is a member of the Deloitte TMT group. He focuses on the areas of federal, international, and multistate tax planning to reduce corporate level tax liability, R&D credit, accounting methods, corporate structuring, credits & incentives, tax controversy matters, mergers & acquisitions, and ASC 740. He has served clients throughout his career that are structured as flow through entities, including S Corp’s, Partnership’s, and LLC’s, as well as C Corporations.
Sepideh Varon, Associate Vice President Health Economics Outcomes Research, Allergan
Sepideh F. Varon, PhD, is Associate Vice President / Head of Global Health Economics Outcomes Research (GHEOR) & Strategy. Her team is comprised of skilled researchers in the US and Internationally who conduct rigorous, innovative and strategically-focused pharmacoeconomic & outcomes research across Allergan’s vast portfolio of products. She joined Allergan 10 years ago, and started as GHEOR Director for the neurosciences therapeutic area where she developed the outcomes research strategy for BOTOX® across multiple indications, including leading health economics & outcomes strategy for the global launch of BOTOX® Chronic Migraine (now approved in 86 countries). Sepi is a seasoned researcher and has published over 40 peer-reviewed manuscripts and has lectured at multiple universities. In addition, she is an Affiliate Assistant Professor at the University of Washington (Seattle, WA) where her department oversees the Allergan – University of Washington fellowship in Pharmaceutical Outcomes Research & Policy.
Gregory Washington, Dean, Samueli School of Engineering, UC Irvine
Dean Gregory N. Washington, Ph.D., joined The Samueli School of Engineering in August 2011. Under his leadership, the school has increased its faculty ranks and numbers of students. He instituted a popular freshman experiential learning program that gives engineering students a taste of real-world product development. He also secured a $9.5 million gift in support of the school's efforts to engage a more diverse student population through STEM outreach.
Nicole Washington, Director of Innovation & Growth, OCTANe
Nicole Washington, M.S., owner of Micro Biz Coach®, works with micro and small business owners to identify strategies that ensure a successful business start-up or boost a veteran business owner’s bottom line. Its clients have been featured on CNBC, Fox Business News, TheStreet.com and a host of Clear Channel radio stations. Nicole has nearly 20 years of systems integration experience, including systems implementation, design and programming from her previous career with Ernst & Young, Whittman Hart and March First management consulting firms. As a management consultant, she worked with several Fortune 500 clients including Sprint, Williams Corporation and Nationwide Insurance.
Anne Wellington, Managing Director, Cedars-Sinai Accelerator
Anne is the Managing Director of the Cedars-Sinai Accelerator, a highly selective accelerator program focused on supporting promising early stage medtech and digital health companies through mentorship and collaboration with Cedars-Sinai. Prior to her current role, she supported the Accelerator program as Entrepreneur-in-Residence. Previously, Anne was Chief Product Officer and a founding team member at Stanson Health, where she developed a clinical decision support and analytics product, recently named by KLAS as the #1 solution for clinical process improvement. Anne has deep expertise in the development and deployment of healthcare IT applications, and has provided product strategy expertise to a variety of leading healthcare technology organizations.
Carol Wells, Senior Director of Commercial Training & Development, Genentech, Pacific Region Chair, Healthcare Businesswomen’s Association
In her current role at Genentech as Senior Director, CMG Training & Development, Carol has responsibility for cross portfolio sales training, management and leadership development, training operations, and functional training that includes marketing, thought leader partnerships, managed care, and medical science.Carol has been with Genentech since 2004. During her career has been a Sales representative, Account Manager, Product Manager, Sales Trainer and has held field management positions from District Manager to Director of Sales. In addition, she was Director of National Accounts at Sanofi-Aventis and General Manager/Vice President of Sales and Marketing at Elan. In 2010 Carol was named one of the “Top 100 Most Inspiring People” by PharmaVoice magazine. She has twice served as president of the San Francisco Bay Area Chapter of the Healthcare Businesswomen’s Association (HBA) in the years 2011 and 2013.
Scott Whitcup, CEO, Akrivista & Whitecap Biosciences
Dr. Scott M. Whitcup has been Executive Vice President, Research and Development, and Chief Scientific Officer since April 2009. Prior to that, Dr. Whitcup was Executive Vice President, Research and Development since July 2004. Dr. Whitcup joined Allergan in January 2000 as Vice President, Development, Ophthalmology. In January 2004, Dr. Whitcup became Allergan's Senior Vice President, Development, Ophthalmology. From 1993 until 2000, Dr. Whitcup served as the Clinical Director of the National Eye Institute at the National Institutes of Health. As Clinical Director, Dr. Whitcup's leadership was vital in building the clinical research program and promoting new ophthalmic therapeutic discoveries. Dr. Whitcup is a faculty member at the Jules Stein Eye Institute/David Geffen School of Medicine at the University of California, Los Angeles. Dr. Whitcup serves on the board of directors of Semnur Pharmaceuticals, a privately-held company. Dr. Whitcup is a former member of the board of directors of Questcor Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company. Dr. Whitcup graduated from Cornell University and Cornell University Medical College. He completed residency training in internal medicine at the University of California, Los Angeles and in ophthalmology at Harvard University, as well as fellowship training in uveitis and ocular immunology at the National Institutes of Health. Dr. Whitcup is a faculty member at the Jules Stein Eye Institute/David Geffen School of Medicine at the University of California, Los Angeles.
Clay Wilemon, CEO & Chief Strategy Officer, DevicePharm
Clay Wilemon is the Chief Executive Officer and Chief Strategy Officer at DevicePharm, Inc. Wilemon has 25 years of experience in medical device marketing with both early-stage companies and global healthcare leaders. He serves as Interim Chair of Tenex Health, Inc. and is an Independent Board of Governors of Sonex Health, LLC.
Alexandra Wilson, SVP Consumer Strategy & Innovation, Allergan
Alexandra Wilkis Wilson is an innovator and a disruptor. She has established herself as a pioneer, leader and dealmaker in digital commerce, retail, merchandising, sales, business development and marketing. She has a proven track record building and operating early stage, fast-growing consumer-facing businesses and creating powerful brands. Alexandra recently became SVP of Consumer Strategy and Innovation for Allergan, the bold, global pharmaceutical company and leader in a new industry model – Growth Pharma. She is creating new sources of revenue for Allergan’s medical aesthetics by building businesses targeting consumers in a revolutionary way never been done before in the pharmaceutical sector.
Bernard Zovighian, Corporate VP & General Manager, Edwards Lifesciences
Bernard J. Zovighian has been corporate vice president since January 2016 and is currently responsible for the company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) business. He joined Edwards Lifesciences in January 2015 as vice president and general manager of the Surgical Heart Valve Therapy (HVT) business, served as corporate vice president of HVT in 2016-2017, and became corporate vice president of TMTT in 2018. Prior to joining Edwards, Zovighian held a variety of roles with increasing levels of responsibility at Johnson & Johnson (J&J) for nearly 20 years. He served as the worldwide president of Advanced Sterilization Products, a J&J company. He was also president of JJMP, J&J’s medical device businesses in Canada. Prior to leading JJMP, Zovighian was with Cordis, a J&J company at the time, for over a decade. Zovighian has extensive senior leadership experience in the medical technology industry in Europe and North America where he has led the development and adoption of disruptive technology that has elevated the standard of care. He received a master’s degree in biomedical engineering from University of Marseille and an executive MBA from Euromed Management, both in France.